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Abstract
Preferential usage of immunoglobulin (Ig) genes that encode antibodies (Abs) against various pathogens is rarely observed
and the nature of their dominance is unclear in the context of stochastic recombination of Ig genes. The hypothesis that
restricted usage of Ig genes predetermines the antibody specificity was tested in this study of 18 human anti-V3 monoclonal
Abs (mAbs) generated from unrelated individuals infected with various subtypes of HIV-1, all of which preferentially used
pairing of the VH5-51 and VL lambda genes. Crystallographic analysis of five VH5-51/VL lambda-encoded Fabs complexed
with various V3 peptides revealed a common three dimensional (3D) shape of the antigen-binding sites primarily
determined by the four complementarity determining regions (CDR) for the heavy (H) and light (L) chains: specifically, the
H1, H2, L1 and L2 domains. The CDR H3 domain did not contribute to the shape of the binding pocket, as it had different
lengths, sequences and conformations for each mAb. The same shape of the binding site was further confirmed by the
identical backbone conformation exhibited by V3 peptides in complex with Fabs which fully adapted to the binding pocket
and the same key contact residues, mainly germline-encoded in the heavy and light chains of five Fabs. Finally, the VH5-51
anti-V3 mAbs recognized an epitope with an identical 3D structure which is mimicked by a single mimotope recognized by
the majority of VH5-51-derived mAbs but not by other V3 mAbs. These data suggest that the identification of preferentially
used Ig genes by neutralizing mAbs may define conserved epitopes in the diverse virus envelopes. This will be useful
information for designing vaccine immunogen inducing cross-neutralizing Abs.
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Introduction
Human monoclonal antibodies (mAbs) against the third variable
domain (V3) of the HIV-1 gp120 envelope protein derived from
HIV-1 infected individuals display the ability to neutralize primary
isolates representing different clades [1,2,3,4,5]. Several anti-V3
mAbs produced in our laboratory neutralized all tested neutral-
ization-sensitive (Tier 1) pseudotyped viruses (psVs) and 30% of
psVs exhibiting a less sensitive (Tier 2) phenotype [4]. Anti-V3
mAbs also protect against viral infection in experimental models
[6,7,8] and could play a similar role when elicited by a HIV
vaccine.
Anti-V3 mAbs display a broad range of cross-neutralizing
activities depending on conserved elements in the V3 loop and
other factors, including immunoglobulin (Ig) gene usage. A study
of Ig variable genes of heavy chains (VH) used by a panel of
human anti-V3 mAbs revealed a significantly altered and
restricted pattern of VH gene usage when compared to other
anti-HIV-1 mAbs [9,10]. One Ig gene in particular, VH5-51, was
preferentially used by 18 of 51 (35%) anti-V3 mAbs, and is not
used by 44 other anti-HIV-1 mAbs specific to the CD4-binding
site (CD4bs), CD4 induced antigen (CD4i) and gp41 [9]. In
contrast, anti-CD4i and anti-gp41 mAbs preferentially used the
VH1-69 gene segment [9,10]. Several other studies have reported
that human Abs against various pathogens also exhibit preferential
VH gene usage. For example, Abs against the capsular
polysaccharide of Hemophilus influenzae type b primarily utilize the
VH3-23 gene [11], Abs against Rotavirus predominantly use the
VH1-46 gene segment [12] while some human mAbs against gly-
coprotein gB of human cytomegalovirus are encoded by a pairing
of the VH3-30 and VL kappa 3 genes [13,14,15].
In the context of stochastic recombination of Ig variable genes
and different pairings of the heavy and light chain genes, the
dominance of one particular VH gene paired in a restricted
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existence of a predetermined structure of the antigen-binding site
which fits to a particular epitope. To test this hypothesis, we
analyzed the crystal structure of five Fabs of VH5-51/VL lambda
genes encoded anti-V3 mAbs in complex with various V3 peptides.
The results confirmed our hypothesis and showed that (a) the
shape of the antigen-binding site is similar in the five VH5-51/VL
lambda encoded V3 mAbs and is primarily formed by the CDR
H1, H2, L1 and L2 domains, (b) the majority of the key contact
residues of the mAbs are the same and germline-encoded, and (c)
the epitopes of these V3 mAbs have a very similar 3D structure.
Furthermore, (d) a single mimotope peptide which mimics this
epitope is recognized by a majority of VH5-51 anti-V3 mAbs, but
not by other non-VH5-51 derived mAbs. These results suggest
that identifying Ig genes preferentially used by neutralizing anti-
HIV-1 mAbs has the potential to indicate the presence of con-
served epitopes/antigens in diverse virus envelopes, which can
then be used to design an immunogen based vaccine which
induces cross-neutralizing Abs.
Results
VH5-51-derived human anti-V3 monoclonal antibodies
Recent analysis of the Ig variable genes coding for the heavy
chains showed that the VH5-51 gene segment was preferentially
used by 18 of 51 (35%) anti-V3 mAbs (Table 1) [9]. These VH5-51
V3 mAbs were generated from unrelated individuals living in the
New York City area, Cameroon and India and infected with clade
B, CRF02_AG and clade C, respectively (Table 1). The amino acid
sequences of the VH and VL fragments of 18 VH5-51 mAbs are
shown in Figure S1A and S1B, respectively. The complementarity
determining regions 3 for the heavy chain (CDR H3) are different
for each mAb indicating their uniqueness (Figure S1A).
Light chain genes used by VH5-51-derived anti-V3 mAbs
Forty-eight light chains of human anti-V3 mAbs were
sequenced to determine VL gene usage. All 18 VH5-51 genes
paired only with lambda variable genes and 14 out of 18 used two
particular lambda genes, L1-47 (n=7) and L3-1 (n=7), while the
remaining four mAbs used L3-10 (n=2), L3-25 (n=1) and L6-57
(n=1) genes (Figure 1 and Table 1). In contrast, the 30 non-VH5-
51 V3 mAbs used both VL genes with a dominance of lambda
(n=20) over kappa (n=10) (Figure 1, Table S1).
We also analyzed the pairing of VH5-51 and VL genes on 11
Abs derived from single B cells of healthy individuals [16]. These
Abs used six kappa and five lambda light chains, and each gene
segment was different with the exception of two Abs paired with
L1-47 (data not shown). Thus we concluded that pairing of VH5-
51 gene with lambda genes in anti-V3 mAbs may reflect their
restricted selection by a specific V3 epitope.
Crystallographic analysis of the V3 epitopes recognized
by VH5-51 mAbs
The specific epitope shapes within the V3 crown targeted by five
VH5-51derivedanti-V3mAbsweredeterminedbycrystalstructures
of their Fabs in complex with three V3 peptides representing the
sequences of MN, NY5 (clade B viruses) and consensus clade A. The
following structure complexes were determined: mAb 1006-15/
V3MN (1006/MN), mAb 2219/V3MN (2219/MN), mAb 2557/
V3NY5(2557/NY5),mAb2258/V3MN(2558/MN),and mAb 4025/
V3ConA (4025/ConA). Structures of three complexes, 1006/MN,
2219/MN and 2557/NY5, were used previously to analyze the
conserved elements of the V3 region [17,18], while complexes 2558/
MN and 4025/ConA were determined for this study (Table 2).
The epitope targeted by each mAb within the V3 loop crown
was defined by calculating the atomic contacts of the residues of
the V3 peptide in the crystallographic complex with that of the
Table 1. Human anti-V3 HIV-1 monoclonal antibodies encoded by the VH5-51 gene segment and analyzed in this study.
# mAb
1 Isotype IGHV IGLV lambda Virus subtype
2 Country of origin Reference
1 257 IgG1 l VH5-51 1-47 B USA [31]
2 782 IgG1 l VH5-51 1-47 B USA [33]
3 908 IgG1 l VH5-51 1-47 B USA [33]
4 1006-15 IgG1 l VH5-51 1-47 B USA [33]
5 2219
3 IgG1 l VH5-51 1-47 B USA [34]
6 2483
3 IgG1 l VH5-51 1.47 B USA [35]
7 2456 IgG1 l VH5-51 3-25 B USA [34]
8 419 IgG1 l VH5-51 6-57 B USA [32]
9 838 IgG1 l VH5-51 3-1 B USA [33]
10 4085 IgG1 l VH5-51 1-47 CRF02_AG Cameroon [9]
11 2557 IgG1 l VH5-51 3-1 CRF02_AG Cameroon [35]
12 2558 IgG1 l VH5-51 3-1 CRF02_AG Cameroon [35]
13 3019 IgG1 l VH5-51 3-1 CRF02_AG Cameroon [2]
14 3694 IgG1 l VH5-51 3-1 H Cameroon [9]
15 3792 IgG1 l VH5-51 3-1 C India [9]
16 3906 IgG1 l VH5-51 3-1 C India [9]
17 4022 IgG1 l VH5-51 3-10 C India [9]
18 4025 IgG1 l VH5-51 3-10 non-B India [9]
1All mAbs were produced from HIV-1-infected individuals using cellular methods as described [31,36];
2Virus subtype which infected the blood donors;
3These two mAbs, 2219 and 2483, which are derived from the same donor, are unique (see CDR H3 sequences in Figure S1).
doi:10.1371/journal.pone.0027780.t001
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LLC, La Jolla, CA) [19]. Only residues with a contact area
$10 A ˚ 2 were considered to be part of the epitope, and the
calculation showed that up to 15 V3 crown residues can interact
with the mAbs. Of these, seven V3 crown residues at positions
P304, P305, P307, P308, P309, P317 and P318 have contacts with
all five VH5-51 V3 mAbs, with the largest contact area between
25 A ˚ 2 to 100 A ˚ 2 (Figure 2A, 2B, Table 3). The remaining eight
residues have minimal (average contact area below 25 A ˚ 2)o rn o
contacts with some mAbs (Figure 2B, Table 3).
The different Fabs were bound to recently defined elements of
the V3 crown: the ‘‘arch’’ at the tip (b-turn) of the V3 loop (P312–
P315), the ‘‘circlet’’ composed of regions in the N- and C-terminal
b-strands of the crown (P306–P309 and P316–P317), and the
‘‘‘band’’ at the N- and C-terminal ends of the V3 crown (P304–
P305 and P318) [17]. For the VH5-51 mAbs, the arch containing
the GPGR/Q motif plays a minor role in binding (Figure 2B).
Instead, there are two clusters of residues, with the largest contact
area (25 A ˚ 2 to 100 A ˚ 2) in the circlet and band regions of the V3
crown that are common contact sites for all five VH5-51 derived
Abs: i) R/K
P304,K
P305 and Y
P318 in the band and ii) I
P307, R/H/
A
P308,I
P309 F/L
P317 in the circlet (Figure 2, Table 3). Interestingly,
at three positions, (P304, P308 and P317), the residues were
different in the three V3 peptides in complex with the various
Fabs, but the contact area in A ˚ 2 was similar, confirming the
tolerance of anti-V3 mAbs for variation at these positions.
Thus, the specific epitopes targeted by five different, cross-
reactive VH5-51 V3 mAbs have a similar 3D structure, consisting
of seven key residues present in the N- and C-terminal sides of the
V3 loop (Figure 2, Table 3).
The V3 epitope defined by VH5-51 mAbs are represented
by a single mimotope
We hypothesized that the remaining 13 VH5-51 anti-V3 mAbs,
which were not crystallized in complex with the V3 peptides, may
recognize the same or similar V3 epitope. To investigate a larger
panel of anti-V3 mAbs for their recognition of this particular V3
conformation, we designed a constrained peptide mimotope which
would preserve the 3D of the VH5-51 derived mAbs 2219, 2557
and 1006-15, as recently described, but would not react with other
anti-V3 mAb that recognize different V3 epitopes [17]. The
mimotope was designed on the basis of X-ray structures which
suggested that a) the central 3 residues of the V3 crown (GPG) do
not play an important role in loop recognition by VH5-51 mAbs,
and b) the termini of the V3 crown are relatively close in space
[17]. These observations suggested the use of a circular
Figure 1. Frequency (percentage) of light chain gene segments used by VH5-51 and non-VH5-51 encoded anti-V3 mAbs. VH5-51
paired exclusively with VL lambda genes, mainly 1-47 and 3-1, while non-VH5-51 paired with 18 various VL gene segments, both kappa and lambda,
with preferential usage of VL lambda 3-25. The latter paired mainly with the VH4-59 gene segment (see Table S1).
doi:10.1371/journal.pone.0027780.g001
Table 2. Crystallography data collection and refinement
statistics.
Parameter
Fab/Peptide
Complex
2558/MN 4025/ConA
Data Collection
Beamline X4C, NSLS X4C, NSLS
Space group C2 P3121
Unit cell dimensions:
a, b, c (A ˚) 102.4, 73.1, 88.7 136.1, 136.1, 73.4
a, b, c (u) 90.0, 122.0, 90.0 90.0, 90.0, 120.0
Wavelength (A ˚) 0.97854 0.97883
Resolution (A ˚) 50-1.60 (1.63–1.60) 40.0-2.0 (2.07–2.00)
Completeness (%) 99.2 (98.4) 98.5 (87.9)
Redundancy 6.1 (6.1) 8.7 (5.0)
I/s 29.1 (4.2) 11.9 (1.2)
Rsym (%)
1 5.4 (43.1) 10.6 (61.6)
Refinement
Resolution (A ˚) 17.2–1.6 39.3–2.0
Number of reflections 72601 52488
Rwork (%) 17.42 17.66
Rfree (%) 20.30 21.34
Rmsd bond length (A ˚) 0.006 0.007
Rmsd bond angles (u) 1.602 1.149
Ramachandran analysis
Favored (%)
2 98.07 96.98
Allowed (%)
2 1.69 3.02
Outliers (%)
2 0.24 0.00
PDB Accession Code 3UJI 3UJJ
1Values for the highest resolution shell are given in parentheses.
2Actual number of residues is indicated in parentheses.
doi:10.1371/journal.pone.0027780.t002
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[20]. With this approach, the N- and C-termini of the V3 crown
were joined via a short linker sequence, AlaSerSerPro, which
creates a b-turn conformation that keeps the two strands together
in the conformation observed in the complexes of VH5-51 mAbs
2219, 2557 and 1006-15. This linker was designed using a protein
structure database search. The closest backbone match was
located in the structure of the panthotenate kinase (PDB ID
2I7P). Simultaneously, the central b-turn at the tip of V3 was
deleted and replaced with a disulfide bond that constrains the
peptide to a loop. Deleting the turn assures that reactivity with
other anti-V3s known to recognize the turn would be disrupted.
The mimotopes thus consisted of CQAFYASSPRKSIHIGAC,
where QAFY represents the C-terminal flank of the V3 crown,
ASSP is the linker, and RKSIHIG represents the N-terminal flank
of the V3 crown. A crystal structure of this mimotope in complex
with the Fab of VH5-51 encoded mAb 2557 revealed the same
manner of interactions as shown in complex of 2557 with four
different V3 peptides [17].
This cyclic mimotope was biotinylated, immobilized on
streptavidin-coated ELISA plates, and tested for reactivity with
48 anti-V3 mAbs whose gene usage was known [9]. Binding
studies showed that 14 of 18 (77.8%) VH5-51 encoded mAbs were
reactive with the mimotope, compared to only 1 of 30 (3.3%) non-
VH5-51 mAbs (Figure 3A and Table S2). The relative affinity of
14 mimotope-reactive mAbs was determined by measuring the
50% maximal binding (‘‘half-max’’) to the mimotope (Figure 3B).
All mAbs were titrated between 10 and 0.00003 mg/ml, and half-
max binding values ranged from 9.3 and 0.001 mg/ml, with the
lower values indicative of higher relative binding affinity. The
results show that the mimotope is recognized only by V3 mAbs
encoded by the VH5-51 but not by the other Ig genes.
The CDR domains primarily determine the shape of the
antigen-binding site
We hypothesized that the VH5-51 V3 mAbs may have a
structurally similar shape of the antigen-binding site (ACS), as they
recognize uniform V3 epitope. This was confirmed by the
Figure 2. The epitopes of five VH5-51-encoded V3 mAbs. The epitopes were defined by atomic interactions of the corresponding Fab
fragments with the three V3 peptides in complex. (A) Contact residues in the V3 peptides for each epitope-Fab complex of the anti-V3 mAbs. The
height of each letter (abbreviations representing various amino acids) is proportional to the contact area of the V3 residue with the Fab fragment. (B)
The contact area (A ˚2) for each residue interacting with Fab. The color for each complex is the same as the label in panel (A).
doi:10.1371/journal.pone.0027780.g002
Table 3. Alignment of the V3 peptide residues at positions 302 to 320 that interact in complex with Fabs of VH5-51 encoded anti-
V3 mAbs
1.
mAb/peptide 302 303 304 305 306 307 308 309 312 313 314 315 316 317 318 319 320
1006/MN K RKR IH IGP R FY
2219/MN K RKR IH IGP R FY
2557/NY5 KKG IA IGP R LY
2558/MN N K RKR IH IGP FY TT
4025/ConA RK I RI GP Q FYAT
Mean area
2 21 7 64 73 18 59 57 69 21 18 0 22 0 40 47 65
1The residues of the V3 peptides with 10 A ˚2 or more buried surface area in complex with Fabs were calculated using ICM-Pro program [19]. The V3 contact residues with
the largest buried surface between 25 A ˚2 to 100 A ˚2 (bold) located in the N-terminal (304, 305, 307, 308 and 309) and C-terminal (317 and 318) strands of the V3 crown.
2Mean contact area (A ˚2) per residue.
doi:10.1371/journal.pone.0027780.t003
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and 4025) in complex with three different V3 peptides (MN, NY5
and consensus A).
Structural alignments of the variable fragment of the heavy and
light chains of five VH5-51 derived Fabs in complex with V3
peptides revealed that the CDRs H1, H2, L1 and L2 loops
superimpose well with a root mean square deviation (RMSD) of
,1A ˚ (Figure 4A). Each of the CDR H3 regions of the five mAbs,
however, has a different structure due to their unique sequences
and do not superimpose at all (Figure 4A, 4B, 4D). CDR L3
domains has less diversity but they are still not well aligned
especially for that of 2557 whose L3 is considerably longer than
the others (Figure 4A, 4B, 4C).
The binding site is shaped like a cradle in which the V3 peptide,
in the form of a b-hairpin, is bound (Figure 4B). The binding site is
formed by (a) the CDR L1 loop interacting with the b-turn in the
V3 arch, (b) the CDR L3 interacting with hydrophobic side of the
circlet, (c) the CDR H3 interacting with the hydrophilic side of the
V3 circlet, and (d) CDRs H1 and H2 interacting with the C- and
N-termini of the V3 crown (the V3 band) (Figure 4B and [17].
Thus, the strong structural commonality in the antigen-binding
site of all five crystallized mAbs is determined primarily by the
CDR H1, H2, L1 and L2 domains. Upon binding of the Fabs to
V3 peptides, only the CDR H3 domain was seen to move towards
the antigen, while the remaining CDR domains are stable and
exhibit the same backbone conformation as in unbound Fab (X-P.
Figure 3. Reactivity of anti-V3 mAbs with the mimotope representing the VH5-51 epitope. (A) Binding of the VH5-51- and non-VH5-51-
derived V3 mAbs to the peptide mimotope. Monoclonal Abs were tested at a concentration of 10.0 mg/ml in plates coated with biotinylated
mimotope at a concentration of 1.0 mg/ml. (B) Relative affinities of mAbs binding to the mimotope as measured by 50% of maximal binding (‘‘half-
max’’) to plates coated with the biotinylated mimotope at a concentration of 1.0 mg/ml. Lower half-max values reflect higher relative affinities.
doi:10.1371/journal.pone.0027780.g003
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to a designed mimotope (Figure 3B) and in contact maps related to
mAb specificity for diverse viral epitopes results largely from
differences in the structure of CDR H3, and less so L3.
The germline-encoded CDR residues of VH5-51 V3 mAbs
play key roles in antigen-antibody interactions
We speculated that the similar shape of the antigen-binding site
of VH5-51 anti-V3 mAbs implied that the residues interacting
with the V3 peptide are at the same position for each mAb.
Crystallographic analysis confirmed our hypothesis, with the key
contact residues in the CDR H1 and H2 regions in all five mAbs;
they include W
H33 in H1 (with some variations at positions H31
and H32) and Y
H52,D
H54 and D
H56 in H2 (Figure 4B, 4D and
Table 4). All of these contact residues are also present at the
corresponding positions in the sequence of the germline VH5-51
gene which is VH genomic precursor for these mAbs (Table 4).
Similarly, the contact residues in the CDR L1 of light chains are
also germline-encoded, although they differ since three VL genes
were used by five VH5-51 mAbs. The two residues in mAbs 1006-
15 and 2219–N
L31 and Y
L32, the three residues in mAbs 2557 –
D
L30,K
L31 and Y
L32, and the two residues in mAbs 2558 and
4025–K
L31 and Y
L32 which reacted with the V3 peptides, are
present in the corresponding germline sequences of lambda light
chain genes (Figure 4B, 4C and Table 5). Only contact residues
N
L30 in mAbs 1006-15 and 2219, and E
L30 in mAb 4025 (Table 5)
are mutated from germline gene. In terms of CDR L2, there is
only one contact residue (E
L51) among the five mAbs which is also
germline-encoded and occurs in mAb 4025 (Table 5).
The contact residues in CDR H3 in five crystallized Fabs are all
different, ranging from two to eight residues (Table 4). Further-
more, their germline origin is inconclusive due to deletion and/or
insertion of nucleotides during Ig gene recombination process.
The CDR L3 is less diverse than the H3 region which is made up
by two germline genes (VL and JL) and only few non-templated
nucleotides are added.
The presence of the key contact residues in the four CDR
domains (H1, H2, L1 and L2) at the same position and which are
Figure 4. Structural similarity of the antigen-binding sites of VH5-51 encoded anti-V3 mAbs. (A) A structural superimposition of the Ca
atoms of the Fab variable domains of complexes 1006/MN (green), 2219/MN (cyan), 2557/NY5 (magenta), 2558/MN (yellow), and 4025/ConA
(salmon). Note the domains of CDR H1, H2, L1 and L2 superimposed well, while that of CDR L3 and H3 is more structurally divergent. (B) Same
superimposition as that in panel (A) but with the key contact residues of the mAbs labeled (all contact residues are shown in Tables 4 and 5). The
position of the V3 is illustrated as a dashed line. (C) and (D) Structural details of the antigen combining sites of the light (C) and heavy chains (D) in the
five complexes.
doi:10.1371/journal.pone.0027780.g004
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that the antigen-binding site has conserved backbone conformation.
Peptide in complex with Fab adapt the shape of the
antigen-binding site
TheV3peptides withthesequence of MN, NY5clade Bviruses and
consensus clade A and in complex with Fabs share an almost identical
backbone structure shown by close superimposition of their Ca atoms
(Figure 5A). There is a slight difference in the superimposition of two
peptides, MN and consensus A, in complex with Fab 2558 and 4025,
respectively, which have different conformations of their carboxyl
terminal end due to different residues interacting with the peptides
(Figure 5A, Figure S2). Since mAb 4025 (as well as mAbs 3694, 3906
and 4085) do not react with the mimotope (Table S2), they may
represent a subfamily of VH5-51 encoded V3 mAbs.
This is in contrast with the backbone conformations of the V3
peptides in complex with Fabs encoded by non-VH5-51 genes
(Figure 5B). As shown, the V3 peptides in complex with Fabs of
non-VH5-51 anti-V3 mAbs–537 (VH3-7, VL2-14) complexed
with MN, 447 (VH3-15, VL1-51) complexed with W2R020, 268
(VH4-59, L3-25) complexed with MN, and 3074 (VH4-59, VL1-
51) complexed with MN–do not superimpose well (Figure 5B)
[17,21]. The different backbone conformations of the V3 peptides
were particularly evident when all Fabs of non-VH5-51 V3 mAbs
were aligned to mAb 2557 in the 2557/NY5 complex. As shown
in Figure 5C, the V3 peptides are adapted to the shapes of the
antigen-binding sites encoded by the different VH and VL paired
genes, resulting in different backbone conformation of the bound
V3 peptides.
From this data, it is apparent that the backbone conformation of
the V3 peptide in complex with the Fab is fully adapted to, and
imprints, the shape of its antigen-binding site which is encoded by
particular pair of Ig genes.
Discussion
Restricted usage of Ig gene segments is rarely observed among
Abs due to the exceptional variability resulting from Ig gene
rearrangements and VH and VL gene pairing. While the me-
chanism of preferential Ig genes selection, when it occurs, is not
clear, we have concluded on the basis of our data that the VH5-
51/VL lambda genes preferentially used by anti-V3 mAbs are
related to a particular conserved epitope in the V3 region of the
HIV-1 envelope.
The crystal structures of five VH5-51/VL lambda derived V3
mAbs in complex with V3 peptides revealed that each Fab
interacted with key residues at the same seven positions in the
crown of the V3 loop, despite the fact that the amino acids at these
positions could vary. The observation that mAbs derived from
unrelated individuals and infected with disparate HIV-1 strains
use the same human Ig variable segment, react with the same key
residues, and recognize a nearly identical overall conformation in
the V3 crown suggest that while V3 is variable in sequence and
structurally flexible, a common structure(s) is retained across
strains. Our results further indicate that the mAbs utilizing the
VH5-51/VL lambda genes possess similarly shaped antigen-
binding sites that are highly suitable for the recognition of this
common and conserved V3 conformation. Thus, preferentially
used Ig genes indicate that antibodies encoded by these genes
recognize a conserved epitope which can be used for design of
HIV vaccine immunogen.
The conserved shape of the binding sites is reflected in the
identical lengths of three CDRs, H1, H2 and L2, and minimal
Table 5. The key contact residues in the CDRs of the variable light chains of the VH5-51 derived anti-V3 mAbs in complex with the
V3 peptides
1.
Germline mAb/peptide CDR L1 CDR L2 CDR L3 Ref.
VL1-47 1006/MN SSNIEN NNY RDD ASWDDSRGGP PDYV [17]
VL1-47 2219/MN SSNVEN NNY RND AAWDDSRG GGPDWV [18]
VL3-1 2557/NY5 KLDDKY QDF QAWDASTGVSGGGTKLTVL [17]
VL3-1 2558/MN ILGDKY EDT QAWDSTLGVV This study
VL3-10 4025/ConA ALPE EKY EDS YSTNSGGTFF FV This study
1In a similar fashion as in Table 4 the contact residues (bold) are those which have more than 10 A ˚2 buried surface area in complex with the V3 peptide. Those contact
residues that are present in the corresponding germline sequence are bold and underlined. The CDR L3, in contrast to CDR H3, is encoded in substantial part by VL
germline gene, and the residues interacting with the peptide are also present in the corresponding germline.
doi:10.1371/journal.pone.0027780.t005
Table 4. The key contact residues in the CDRs of five anti-V3 mAbs in complex with V3 peptides
1.
mAb/peptide CDR H1 CDR H2 CDR H3 Ref.
1006/NY5 GYTFTD DHW IYPGDSDTA R L LHYSDRSGSY YFN NDVFHM [17]
2219/MN GYSFSD DHW FYPGDSDSA R L LGGD DYE EDS SGADAFDF [18]
2557/MN GYNFLD DSW IYPDDSDA TRLYL LFEGAQSSN NAFDL [17]
2558/MN GYSFSNYW VYPDDSDSA R L LGF FEGD DYSGSFFDY This study
4025/ConA GYSFSSYW IYPADSDT AILGFWGANR RGGGGMDV This study
1The contact residues (bold) of mAbs with more than 10 A ˚2 buried surface area in complex with V3 peptide were calculated using ICM program [19]. The majority of
these residues (bold, underlined) in CDR H1 and H2 are also present in the corresponding VH5-51 germline gene.
doi:10.1371/journal.pone.0027780.t004
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loops contribute to the structure of the antigen-binding site [22],
and if the lengths are almost identical, then the backbone
conformation of the binding sites is highly comparable. Indeed,
the conserved cradle shape and the four CDRs comprising
this cradle (H1, H2, L1 and L2) have the same superimposed
backbone conformation (Figure 4). Generally, the CDR loops,
with the exception of H3 and L3, have a very limited number of
canonical conformations which support a conserved structure of
the binding site [23,24].
The antigen-binding site of the VH5-51 derived V3 mAbs has a
very stable backbone conformation which was not changed when
Fabs were complexed with different V3 peptides. A similarly stable
structure of the binding site was recently observed in a mAb
against the hepatitis B virus [25]. The shape of the binding site was
not changed in the peptide-bound Fab compared to the
uncomplexed Fab, with the exception of CDR H3 which adapted
to the antigen by changing its conformation upon complexing with
the peptide. Similarly, in murine anti-V3 mAbs, only CDR H3
changed conformation upon peptide binding, with additional
rotation of the VL region relative to the VH chain [25,26]. In our
preliminary structural studies of free and peptide-bound VH5-51
anti-V3 Fabs, only the CDR H3 domain changed its backbone
conformation upon peptide binding, while the shape of the
binding site was stable (data not shown).
The CDR H3 domain has the special function of determining
the fine specificity in each antibody [27]. The structure of H3 is
likely a result of affinity maturation, as it had different sequences,
lengths and conformations. Previously we observed that three
VH5-51 encoded mAbs (2219, 2557 and 2558) neutralized
different numbers of pseudotyped viruses, especially resistant Tier
2 viruses, which might depend on differences in affinity and/or
specificity [4]. While all three mAbs share conserved structure of
the binding sites (Figure 4A), the CDR H3 loops are quite distinct
(Table 4) and may contribute to the differences in neutralizing
activity. Thus, the general structure of the binding site, as
determined by the non-H3 CDRs, appears to mediate the
recognition of the overall shape of the antigen, while each CDR
H3 domain may contribute to Ab affinity and/or fine specificity;
this would be consistent with previous results [27,28].
We hypothesize that the structure of the antigen-binding sites in
the naı ¨ve B cell germline-encoded B cell receptor and in the
affinity-matured mAbs are similar, based on the observation that
the key contact residues in the heavy and light chains of
crystallized Fabs are germline-encoded (Table 4 and 5). We
further speculate that a mimotope which specifically binds to 14 of
18 VH5-51 encoded anti-V3 mAbs, but is not reactive with non-
VH5-51 V3 mAbs, binds to the receptor encoded by the VH5-51/
lambda genes on the naı ¨ve B cells. Consequently, these B cells may
be selected and stimulated to produce Abs specific for the relatively
conserved V3 epitopes upon immunization with a mimotope-
based immunogen.
We have shown that the V3 sequence-fusion proteins used as
boosting immunogens after gp120 DNA priming were immuno-
genic and induced neutralizing Abs in rabbits [29]. Further
experiments in rabbits have demonstrated that one of immuno-
gens containing the V3 sequence recognized by mAb 2219, which
is encoded by VH5-51 and VL1-47 genes, elicited cross-clade
neutralizing activity [30] predicting that a mimotope-based
immunogen has potential to induce V3-specific Abs with
neutralizing activity.
Collectively, we have observed in this study that the preferential
usage of the VH5-51 gene paired with VL lambda genes in a
restricted manner forms the antigen-binding site which allows
Figure 5. Structures of V3 peptides in complex with the VH5-51
and non-VH5-51 anti-V3 mAbs. (A) Structural superimposition of
the Ca atoms of the V3 peptides in the complexes with five VH5-51
mAbs: 1006/MN (green), 2219/MN (cyan), 2557/NY5 (magenta), 2558/
MN (yellow), and 4025/ConA (salmon). (B) For comparison, a structural
superimposition of the V3 peptides complexed with non-VH5-51 mAbs:
537/MN (grey), 447/W2RW020 (violet), 3074/MN (orange), and 268/MN
(teal); the complex of Fab with V3 peptide, 2557/NY5 (magenta), is
retained for comparison. (C) V3 peptides in the various crystals noted in
B after superimposing the Fab structures onto that of Fab 2557 (shown
as a semi-transparent surface). Note the drastically different ways of
binding V3 for the non-VH5-51 mAbs.
doi:10.1371/journal.pone.0027780.g005
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identification of dominantly used Ig genes by antibodies, including
neutralizing anti-HIV-1 mAbs, may allow for the discovery of
novel conserved epitopes. It may have practical implications for
the design of a vaccine immunogen targeting antigenically diverse
pathogens such as HIV-1.
Materials and Methods
Ethics Statement
The study was approved by the New York University School of
Medicine Institutional Review Board. All subjects signed written
approved informed consentformspriorto participating inthe study.
Human anti-V3 mAbs
Forty-eight human anti-V3 HIV-1 mAbs were tested in this
study. Eighteen mAbs are encoded by the VH5-51 gene segment
(Table 1) and were selected from the panel of anti-V3 mAbs
studied for Ig gene usage in the previous study [9]. Many of these
were previously shown to neutralize HIV pseudoviruses and/or
primary isolates from multiple subtypes and, thus, are considered
to be cross-strain and cross-clade reactive [2,9,31,32,33,34,35]. All
mAbs were produced in our laboratory by cellular methods via
fusion of heteromyeloma cells with Epstein-Barr virus transformed
PBMCs derived from individuals infected with clade B and non-
clade B HIV-1; the resulting heterohybridoma cell lines were
cloned by limiting dilution to monoclonality as previously de-
scribed [31,32,36]. This method preserves the cognate pairing of
the heavy and light chain genes and the mAbs thus accurately
represent portions of the human B cell repertoire. Protein A or G
purified mAbs were used for immunochemical and crystallo-
graphic analyses. The VH and VL sequences are available at
GenBank (accession nos. M67504, EU794410, EU794414-17,
EU794424, EU794427-28, EU794430, EU794434, EU794437,
EU794441-3 and HQ890341–HQ890361).
Peptides
Two 23-mer V3 peptides representing the sequences of clade B
MN (
301YNKRKRIHIGPGRAFYTTKNIIG
325) and consensus
clade A (
301NNTRKSIRIGPGQTFYATGDIIG
325) [17,33] were
used to make complexes with the Fab fragments of mAbs 2558
and 4025, respectively. The V3 peptides MN and NY5
(
301NNTKKGIAIGPGRTLYAREK
322) were used for crystalliza-
tion of 1006-15, 2219 and 2557 as previously described [17]. A
mimotope, CQAFYASSPRKSIHIGAC, mimicking the specific
V3 epitope recognized by the VH5-51 derived human mAbs that
contains elements of the N- and C- b-strands of the V3 crown
connected by a linker sequence (ASSP), with the GPGR motif
replaced by a disulfide bridge, was previously described [17].
RT-PCR amplification of the Ig variable region of the light
chain genes
The messenger RNA was extracted from hybridoma cell lines
producing human anti-V3 mAbs and reverse transcribed into
cDNA using oligo dT primer. A homopolymeric dCTP tail was
added to the 39 end of the total cDNA with terminal deoxynucleo-
tidyl transferase. The variable domain of the lambda light chain
genes (VL) was amplified from poly-C tailed cDNA by PCR using
deoxyinosine-containing anchor primer as forwards primer
(59RACE Abridged Anchor primer, 59-GGC CAC GCG TCG
ACT AGT ACG GGI IGG GII GGG IIG-39) (Invitrogen) and
gene specific primer as backwards primer located in constant region
of k (59-AAC ACT CWY YCC TGT TGA AGC TCT T-39)o rl
(59-CAC TGT CTT CTC CAC GGT GCT CCC TTC-39).
PCR amplification was performed using a cycling program of
2 min at 94uC, 35 cycles of 60 s at 94uC, 60 s at 55uC, and 120 s
at 72uC, followed by 7 min at 72uC. Ethidium bromide-stained
0.8% agarose gels were used to visualize the PCR products. The
bands of the appropriate size were excised and cleaned with
GeneElute Minus EtBr Spin Column (Sigma) then were cloned
into 2.1-TOPO TA cloning (Invitrogen).
For each chain, 6 to 12 independent clones were screened. The
plasmids with the appropriate inserts were sequenced in both
directions using the M13 primers. All sequencing reactions were
performed at the Macrogen, Rockville, MD. The sequence data were
analyzed using Pregap4, BioEdit software and the International
ImMunoGene Tics (IMGT) information system (http://imgt.cines.fr).
ELISA
A standard ELISA was used to determine the binding of mAbs
to the mimotope as previously described [33]. The biotinylated
mimotope was immobilized on streptavidin-coated plates (Strep-
taWell, Roche), blocked with 2% BSA in phosphate-buffered
saline (PBS), and then incubated for 1.5 h at 37uC with human
mAbs at concentrations ranging from 0.00003 to 10 mg/ml. The
plates were washed, and the bound mAbs were detected by
incubation with alkaline phosphate-conjugated goat anti-human
IgG (Fc) (Zymed, San Francisco, CA) for 1.5 h at 37uC. After
washing, the substrate was added for 30 min and the plates were
read at 410 nm. The relative affinity of mAb binding to mimotope
was assessed by measuring the concentration of mAb that gave
50% maximal binding; it was calculated by linear interpolation
when the binding reached the saturation level.
X-ray crystallography
Crystallization of Fabs in complex with V3 peptides was carried
out to obtain the atomic structures of the antigen combining sites of
the mAbs and their relationship to VH and VL gene usage. Briefly,
Fab of each mAb was prepared by papain digestion followed by
purification using Protein A affinity columns (GE Healthcare) and
size exclusion chromatography [37]. Excess epitope peptide was
added to the Fab solution and the Fab/V3 mixture was
concentrated to 10–30 mg/ml for crystallization. Standard vapor
diffusion techniques were used with sitting or hanging drop trays
[21]. X-ray diffraction data were collected at the National
Synchrotron Light Source at Brookhaven National Laboratory.
The crystal structures were solved by the molecular replacement
method using information on the sequence of the Ig heavy and light
chains determined in our laboratory and from known Fab models
using CNS [38] or MOLREP [39]. The structure refinement was
carried out using the CNS or REFMAC [40].
Supporting Information
Figure S1 Amino acid sequences of the variable fragment of the
heavy chains (A) and light chains (B) of 18 human anti-V3 mAbs
encoded by the VH5-51 gene segment. The sequences are aligned
with their corresponding germlines (the sequences of the heavy
chains were aligned only to one germline sequence of IGHV5-
51*01 according to IMGT system). Kabat numbering is used
along with the IMGT CDR domain definitions. Insertion codes
are shown as lowercase letters in the numbering line, following the
‘‘base’’ residue number for that insertion (e.g. the first ‘‘a’’ in the
heavy chain figure, which follows residue 52, is for residue 52A).
For CDRs H3 and L3, insertion codes are represented as ‘‘x’’ to
preserve the alignment. Dots indicate identity, while letters
indicate substitutions in the heavy and light chains. CDR H3
and Framework 4 are not aligned to germlines.
(TIF)
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peptides in the V3-Fab complexes. The key contact residues of the
Fabs in the light and heavy chains are labeled and numbered
according to the standard Kabat numbering scheme.
(TIF)
Table S1 Immunoglobulin gene usage for variable light chain of
non-VH5-51 anti-V3 mAbs.
(DOC)
Table S2 ELISA reactivity of VH5-51 and non-VH5-51
encoded anti-V3 mAbs with cyclic biotinylated mimotopes
1.
(DOC)
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